

REMARKS

In the Office Action mailed February 26, 2006, the Applicants were advised that they had failed to comply with the species selection requirement, and did not elect a single species of anti-heparanase antibody of a specific amino acid sequence as required by the Restriction Office actions dated July 6, and October 23, 2006.

Applicants regret the oversight, and elects, as a species selection, a full length monospecific monoclonal antibody that is capable of binding to at least one epitope of a heparanase protein that is at least 90% homologous to SEQ ID NO:4, said epitope being at least 90% homologous to SEQ ID NO:9 and wherein said epitope is a catalytic nucleophilic sequence of a heparanase protein, said antibody being HP3/17.

It is believed that amended Claims 1, 5, 6, 9, 35, 59, 63, 64, 67, 93, 117, 120, 130, 133, 151, 178, 188, 191, 208, 233, 236, 237, 241, 248, 255, 256, 260, 267, 268, 271, 274, 279, 280, 283, 291, 294, 295, 299, 311, 312, 318, 321, 326, 338, 339, 345, 359, 360, 364, 367 and 368, and original claims 22-34, 45, 46, 55-58, 80-92, 113-115, 138-150, 160, 161, 171-175, 195-207, 217-218, 228, 233, 242-247, 249-251, 261-266, 268-270, 281-290, 300-310, 313-317, 327-337, 340-341, 351-353, 355, 365, 369 and 370 are readable on the selected species. It is believed that original claims 19-21, 77-79, 135-137 and 192-194 do not read on the selected species.


Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to the non-elected Group.

PRELIMINARY AMENDMENTS

Applicants have now cancelled Claims 2-4, 7, 8, 10-18, 36-44, 47-54, 60-62, 65, 66, 68-76, 94-112, 118-119, 121-129, 131-132, 134, 152-159, 162-170, 176, 177, 179-187, 189, 190, 209-216, 219-227, 234, 235, 238, 240, 252-254, 257-259, 272, 273, 275-278, 292, 293, 296-298, 319, 320, 322-325, 342-344, 347-349, 356-358 and 361-363. Further, Claims 1, 5, 6, 9, 35, 59, 63, 64, 67, 93, 117, 120, 130, 133, 151, 178, 188, 191, 208, 233, 236, 237, 241, 248, 255, 256, 260, 267, 268, 271, 274, 279, 280, 283, 291, 294, 295, 299, 311, 312, 318, 321, 326, 338, 339, 345, 359, 360, 364, 367 and 368 have now been amended to read on human heparanase and homologs thereof, having at least 90 homology to SEQ ID NO: 4; and epitopes thereof having at least 90% homologous amino acid sequence to that of SEQ ID NO: 4. Support for such an amendment is found throughout the instant specification and claims, for example now cancelled claims 4 and 5, and 14. Thus, the proposed amendments do not constitute introduction of new matter.

Favorable examination is earnestly solicited.

Respectfully submitted,

A handwritten signature in cursive script, reading "Martin D. Moynihan". The signature is written in dark ink and is positioned above the printed name and registration number.

Martin D. Moynihan

Registration No. 40,338

Date: March 22, 2007